Original articleLamotrigine monotherapy in children
Introduction
Lamotrigine (LTG) is a novel antiepileptic drug (AED) labeled for adjunct treatment of refractory focal-onset and secondarily generalized epilepsies in adults [1], [2]. Recently, it has received Food and Drug Administration approval for monotherapy in adults with focal-onset seizures. Despite this labeling, it appears to have a broad spectrum of activity against a variety of seizure types and epileptic syndromes [1], [2]. Few data exist on the effectiveness of this agent as a firstline drug in the treatment of epilepsy or as a monotherapeutic agent in children. We retrospectively examined the effectiveness of LTG as a monotherapeutic agent for a variety of pediatric epilepsies.
Section snippets
Methods
The study was conducted at the M.S. Hershey Medical Center from April 1995 to April 1997. Children treated with LTG monotherapy were identified through a retrospective chart review. To be included in the study, all children had to have a diagnosis of epilepsy with at least two unprovoked seizures before initiation of LTG therapy and had to be receiving LTG for at least 1 month. Where possible, children were classified as having either focal or generalized epilepsies and specific epileptic
Results
Eighty-three children (36 males and 47 females) were included, with an average age of 8.7 years (range 18 months to 20 years). One patient was an adult (20 years of age) who was included because she was diagnosed with juvenile myoclonic epilepsy in early adolescence and was transitioned to LTG because of intolerable side effects from valproate. Fourteen were newly diagnosed patients (AED naive); the remaining 69 were taking other AEDs and were transitioned to LTG monotherapy or had a remote
Discussion
The results of the present retrospective review of pediatric patients treated with LTG monotherapy suggests that LTG is effective as a monotherapeutic agent for a variety of pediatric epilepsies. Overall, 45% of children in this study treated for at least 6 months with LTG monotherapy were seizure free. In previously untreated children, remission was achieved in 38%. LTG appeared equally effective in children with either focal-onset or generalized epilepsies.
LTG is an effective monotherapeutic
Acknowledgments
We thank T. Kuhn, PhD for his editorial comments and M. Weidler for assistance in the preparation of the manuscript.
References (21)
- et al.
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Lancet
(1995) - et al.
LamotrigineA review of its pharmacological properties and clinical efficacy in epilepsy
Drugs
(1993) - et al.
Overview of the clinical efficacy of lamotrigine
Epilepsia
(1991) - Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised...
- et al.
An active-control trial of lamotrigine monotherapy for partial seizures
Neurology
(1998) - Chapman A, Yuen AWC, and 106 Investigators. Lamotrigine (Lamictal) versus carbamazepine as monotherapy in patients with...
- et al.
Clinical experience with lamotrigine (Lamictal) monotherapy for partial seizures in adult outpatients
Epilepsia
(1992) - Brodie MJ, Richens A, and the UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lamotrigine versus carbamazepine: A...
- et al.
Lamotrigine in treatment of 120 children with epilepsy
Epilepsia
(1994) - et al.
Lamictal is effective for add-on treatment of partial seizures in children and adolescents
Epilepsia
(1997)